



# Ambulatory Care Quarterly Performance Summary



Ambulatory Care Monthly Performance Summary

FY 2019 - 2020

Program	Metric	Description	Metric Worth	Target	July	August	September	October	November	December
PRIME	1.1.1/ 1.2.1	Alcohol and Drug Missue: SBIRT	\$ 686,621.23	13.68%	19.39%	19.93%	20.28%	20.27%	20.52%	19.42%
PRIME	1.1.1/ 1.2.1	Alcohol and Drug Missue: Brief Screening Only	\$ 686,621.23	54.54%	52.04%	51.08%	50.48%	50.13%	57.71%	60.07%
PRIME	1.1.3/ 1.2.4	Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%)^	\$ 1,373,242.45	29.68%	20.01%	19.91%	20.32%	20.67%	20.31%	20.55%
PRIME	1.1.5/ 1.2.12	Screening for Clinical Depression and follow-up^	\$ 1,373,242.45	65.37%	61.80%	60.89%	60.34%	60.07%	60.68%	61.83%
PRIME	1.1.6/1.2.14/	Tobacco Assessment and Counseling^	\$ 1,974,662.50	97.35%	98.32%	98.39%	98.44%	98.59%	98.63%	98.57%
PRIME	1.1.7	Depression Remission or Response for Adolescents and Adults (DRR): Response*	\$ 240,568.02	8.45%	8.31%	8.27%	8.60%	8.57%	8.74%	6.98%
PRIME	1.1.7	Depression Remission or Response for Adolescents and Adults (DRR): Remission*	\$ 240,568.02	4.52%	4.19%	4.20%	4.27%	4.21%	4.37%	3.55%
PRIME	1.1.7	Depression Remission or Response for Adolescents and Adults (DRR): Follow up*	\$ 240,568.02	24.30%	22.63%	22.73%	23.26%	23.13%	23.09%	21.11%
PRIME	1.2.10	Controlling Blood Pressure Disparity Reduction	\$ 651,538.39	67.15%	?	?	65.97%	61.91%	67.03%	66.56%
PRIME	1.2.11	REAL Data Completeness	\$ 651,538.39	80.00%	88.86%	60.05%	86.09%	84.62%	85.45%	85.93%
PRIME	1.2.13	SOGI Data Completeness	\$ 651,538.39	40.00%	68.28%	?	91.89%	91.99%	92.04%	92.09%
PRIME	1.2.2	CG-CAHPS: Provider Rating (NRC)*	\$ 651,538.39	81.15%	81.05%	81.13%	81.39%	81.77%	81.88%	82.02%
PRIME	1.2.3	Colorectal Cancer Screening^	\$ 651,538.39	58.52%	58.37%	58.11%	58.09%	57.68%	57.41%	57.14%
PRIME	1.2.5/ 1.5.1	Controlling Blood Pressure^	\$ 1,252,958.44	71.39%	73.15%	72.24%	72.01%	61.91%	67.03%	66.56%
PRIME	1.2.7/ 1.5.2	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	\$ 1,252,958.44	91.42%	92.80%	93.19%	93.45%	93.12%	93.28%	93.33%
PRIME	1.2.8	Prevention Quality Overall Composite #90 (PQI90)	\$ 651,538.39	0.79%	?	?	0.81%	0.77%	0.76%	?
PRIME	1.3.1	Closing the referral loop: Receipt of Specialist (CMS504)	\$ 701,656.73	51.32%	98.27%	98.33%	48.08%	48.64%	48.98%	?
PRIME	1.3.3	Influenza Immunization*	\$ 701,656.73	73.40%	68.09%	68.92%	73.45%	44.01%	54.36%	65.90%
PRIME	1.3.5	Request for Specialty Care Expertise Turnaround Time	\$ 701,656.73	70.66%	75.76%	75.48%	75.50%	75.75%	75.82%	?
PRIME	1.3.6	Specialty Care Touches: Specialty expertise requests managed via non-face to face	\$ 701,656.73	10.20%	?	?	?	?	9.47%	?
PRIME	1.3.7	Tobacco Assessment and Counseling (Specialty)*	\$ 701,656.73	97.35%	98.32%	98.39%	98.44%	98.59%	98.63%	?
PRIME	1.5.3	PQRS # 317 Preventative Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	\$ 601,420.05	92.29%	92.07%	91.91%	92.56%	?	?	?
PRIME	2.2.3	Medication Reconciliation - 30 days*	\$ 577,363.25	92.23%	91.54%	91.56%	91.43%	91.48%	91.31%	91.64%
PRIME	2.3.2	Medication Reconciliation - 30 days (Chronic Pop)*	\$ 1,154,726.50	91.65%	93.87%	93.75%	93.40%	93.08%	93.27%	93.89%
PRIME	2.4.1	Adolescent Well Care Visit (Fosters)	\$ 577,363.25	67.00%	60.19%	?	?	?	57.55%	52.38%
PRIME	2.4.2	Dev Screening First Three Years of Life	\$ 577,363.25	59.97%	54.79%	?	?	?	44.59%	49.66%
PRIME	2.4.3	Documentation of Current Medications (Foster)	\$ 577,363.25	85.72%	84.84%	?	?	?	84.72%	84.27%
PRIME	2.4.4	Depression Screening and Follow-up (Fosters)	\$ 577,363.25	61.14%	54.79%	?	?	?	61.90%	60.94%
PRIME	2.4.5	Tobacco (Fosters)	\$ 577,363.25	97.35%	100.00%	?	?	?	100.00%	98.11%
PRIME	2.4.7	Well Child Visits 3rd, 4th, 5th, 6th Years (Fosters)	\$ 577,363.25	83.70%	85.19%	?	?	?	81.75%	73.91%
PRIME	2.4.8	Comprehensive Medical Evaluation Following Foster Placement	\$ 601,420.05	84.00%	?	?	?	?	27.38%	26.39%
QIP	PC1	Comprehensive Diabetes Care: A1C control (<8%)*	\$ 1,382,400.00	59.49%	64.09%	64.48%	64.77%	63.97%	63.85%	62.38%
QIP	PC10	Childhood Immunization Status (CIS) Combination 10**	\$ 1,382,400.00	36.60%	14.62%	33.72%	33.72%	33.42%	39.13%	35.90%
QIP	PC12	Chlamydia Screening in Women Ages 16-24	\$ 1,382,400.00	?	?	?	?	?	?	?
QIP	PC2	Comprehensive Diabetes Care: Eye Exam*	\$ 1,382,400.00	55.18%	53.19%	54.36%	53.82%	57.13%	57.81%	58.99%
QIP	PC3	Comprehensive Diabetes Care: BP Control	\$ 1,382,400.00	75.99%	77.14%	78.82%	77.74%	75.40%	74.70%	74.61%
QIP	PC4	Asthma Medication Ratio (AMR)	\$ 1,382,400.00	66.47%	?	?	?	?	?	?
QIP	PC5	Medication Reconciliation Post Discharge (MRP)*	\$ 1,382,400.00	60.62%	59.81%	59.61%	59.42%	60.05%	59.85%	61.86%
QIP	PC7	Children and Adolescent Access to PCP (CAP): 25 mos – 6 yrs*	\$ 345,600.00	88.06%	84.83%	85.24%	85.24%	92.76%	85.28%	85.24%
QIP	PC7	Children and Adolescent Access to PCP (CAP): 12-19 yrs*	\$ 345,600.00	87.89%	82.83%	83.61%	83.61%	84.05%	84.14%	84.32%
QIP	PC7	Children and Adolescent Access to PCP (CAP): 7-11 yrs*	\$ 345,600.00	90.71%	86.76%	86.83%	86.83%	86.61%	86.68%	86.96%
QIP	PC7	Children and Adolescent Access to PCP (CAP): 12-24 mos*	\$ 345,600.00	95.73%	94.67%	92.28%	92.28%	93.44%	91.43%	91.46%
QIP	PC9	Immunizations for Adolescents (IMA) Combination 2*	\$ 1,382,400.00	39.38%	37.66%	37.14%	36.50%	35.72%	36.07%	37.16%
QIP	SC1	Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy*	\$ 1,382,400.00	80.71%	79.23%	77.58%	76.22%	75.37%	85.71%	71.11%
QIP	SC2	Coronary Artery Disease (CAD): Antiplatelet Therapy*	\$ 1,382,400.00	88.00%	88.54%	89.35%	88.95%	88.17%	87.16%	87.24%
QIP	SC3	Coronary Artery Disease (CAD): ACE- Inhibitor or ARB Therapy – Diabetes or LVEF<40%*	\$ 1,382,400.00	85.92%	85.43%	85.46%	86.22%	87.39%	88.74%	87.12%
QIP	SC4	Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior MI or LVEF<40%*	\$ 1,382,400.00	90.00%	89.86%	89.41%	89.66%	92.54%	92.54%	91.55%
QIP	SC5	Heart Failure (HF): ACE-Inhibitor or ARB Therapy for LVSD	\$ 1,382,400.00	83.00%	91.40%	90.65%	89.01%	85.11%	86.11%	84.72%
QIP	SC6	Heart Failure (HF): Beta-Blocker Therapy for LVSD	\$ 1,382,400.00	88.00%	94.62%	?	94.51%	91.49%	89.69%	90.43%

\*PSOA Incentive Measure    ^UDS Measures